OA11653A - Pharmaceutical agents for the treatment of parkisnon's disease, ADHD and microadenomas. - Google Patents

Pharmaceutical agents for the treatment of parkisnon's disease, ADHD and microadenomas. Download PDF

Info

Publication number
OA11653A
OA11653A OA1200100068A OA1200100068A OA11653A OA 11653 A OA11653 A OA 11653A OA 1200100068 A OA1200100068 A OA 1200100068A OA 1200100068 A OA1200100068 A OA 1200100068A OA 11653 A OA11653 A OA 11653A
Authority
OA
OAPI
Prior art keywords
pharmaceutically acceptable
adhd
sait
receptor
adrenergic receptor
Prior art date
Application number
OA1200100068A
Other languages
English (en)
Inventor
Elisa Rse Jackson
Stafford Mclean
Stevin Howard Zorn
Original Assignee
Spfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spfizer Products Inc filed Critical Spfizer Products Inc
Publication of OA11653A publication Critical patent/OA11653A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA1200100068A 1998-09-21 1999-09-03 Pharmaceutical agents for the treatment of parkisnon's disease, ADHD and microadenomas. OA11653A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10119198P 1998-09-21 1998-09-21
US10386898P 1998-10-12 1998-10-12

Publications (1)

Publication Number Publication Date
OA11653A true OA11653A (en) 2004-12-08

Family

ID=26798000

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100068A OA11653A (en) 1998-09-21 1999-09-03 Pharmaceutical agents for the treatment of parkisnon's disease, ADHD and microadenomas.

Country Status (38)

Country Link
US (2) US6300329B1 (zh)
EP (1) EP1115402A1 (zh)
JP (1) JP2002526448A (zh)
KR (3) KR20040054752A (zh)
CN (1) CN1319013A (zh)
AP (1) AP1456A (zh)
AR (1) AR029739A1 (zh)
AU (1) AU760230B2 (zh)
BG (1) BG105445A (zh)
BR (1) BR9913975A (zh)
CA (1) CA2344670A1 (zh)
CO (1) CO5140075A1 (zh)
CZ (1) CZ20011006A3 (zh)
DZ (1) DZ2894A1 (zh)
EA (2) EA200100204A1 (zh)
EE (1) EE200100179A (zh)
GE (1) GEP20033081B (zh)
GT (1) GT199900154A (zh)
HN (1) HN1999000146A (zh)
HR (1) HRP20010209A2 (zh)
HU (1) HUP0103691A3 (zh)
ID (1) ID28028A (zh)
IL (2) IL164839A0 (zh)
IS (1) IS5852A (zh)
MA (1) MA26690A1 (zh)
MY (1) MY127939A (zh)
NO (1) NO20011409L (zh)
NZ (1) NZ509855A (zh)
OA (1) OA11653A (zh)
PA (1) PA8482001A1 (zh)
PE (1) PE20001084A1 (zh)
PL (1) PL346904A1 (zh)
SK (1) SK3592001A3 (zh)
TN (1) TNSN99177A1 (zh)
TR (2) TR200101357T2 (zh)
TW (1) TW518225B (zh)
WO (1) WO2000016777A1 (zh)
YU (1) YU21701A (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AU2002315336A1 (en) * 2001-06-18 2003-01-02 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5ht-1a agonists
US20030036555A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Kg Pramipexole for the treatment of ADHD
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
EP1765075A4 (en) * 2004-06-10 2010-11-10 Mclean Hospital Corp PYRIMIDINES, IN PARTICULAR URIDINE, USED IN TREATMENTS ON PATIENTS WITH BIPOLAR DISORDERS
EP1784199A4 (en) * 2004-08-11 2010-06-23 Mclean Hospital Corp COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
TW200800306A (en) 2005-09-12 2008-01-01 Wyeth Corp Sustained-release formulation and uses thereof
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
US11426366B2 (en) 2015-05-15 2022-08-30 Arizona Board Of Regents On Behalf Of The Universsity Of Arizona Compositions and methods for treating motor disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008148A1 (en) * 1989-01-23 1990-07-26 Pfizer Inc. Bis-aza-bicyclic anxiolytic agents
WO1992000075A1 (en) * 1990-06-29 1992-01-09 Pfizer Inc. Pyridopyrazine derivatives for treating substance abuse and addiction
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
PT765320E (pt) * 1994-06-14 2002-02-28 Pfizer Derivados da benzimidazolona com actividade dopaminergica central
US5877183A (en) * 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

Also Published As

Publication number Publication date
GEP20033081B (en) 2003-10-27
MA26690A1 (fr) 2004-12-20
KR100468340B1 (ko) 2005-01-27
HN1999000146A (es) 2000-11-11
EP1115402A1 (en) 2001-07-18
US6608064B2 (en) 2003-08-19
JP2002526448A (ja) 2002-08-20
AP1456A (en) 2005-09-30
EA200100204A1 (ru) 2001-08-27
NO20011409L (no) 2001-03-28
PA8482001A1 (es) 2000-05-24
PE20001084A1 (es) 2000-10-18
TR200402083T2 (tr) 2004-10-21
KR20040054752A (ko) 2004-06-25
YU21701A (sh) 2004-07-15
AP2001002102A0 (en) 2001-03-31
CN1319013A (zh) 2001-10-24
KR20010075222A (ko) 2001-08-09
TR200101357T2 (tr) 2001-08-21
KR20030088512A (ko) 2003-11-19
ID28028A (id) 2001-05-03
US6300329B1 (en) 2001-10-09
IS5852A (is) 2001-02-20
TNSN99177A1 (fr) 2005-11-10
SK3592001A3 (en) 2001-12-03
WO2000016777A1 (en) 2000-03-30
PL346904A1 (en) 2002-03-11
AU760230B2 (en) 2003-05-08
GT199900154A (es) 2001-03-06
CA2344670A1 (en) 2000-03-30
CZ20011006A3 (cs) 2001-09-12
AR029739A1 (es) 2003-07-16
BG105445A (en) 2001-12-29
NZ509855A (en) 2003-04-29
IL164839A0 (en) 2005-12-18
TW518225B (en) 2003-01-21
HRP20010209A2 (en) 2002-04-30
BR9913975A (pt) 2001-06-19
US20010034347A1 (en) 2001-10-25
CO5140075A1 (es) 2002-03-22
AU5383199A (en) 2000-04-10
NO20011409D0 (no) 2001-03-20
HUP0103691A2 (hu) 2002-02-28
DZ2894A1 (fr) 2003-12-15
EE200100179A (et) 2002-10-15
HUP0103691A3 (en) 2003-01-28
EA200301063A1 (ru) 2004-12-30
IL141507A0 (en) 2002-03-10
MY127939A (en) 2007-01-31

Similar Documents

Publication Publication Date Title
OA11653A (en) Pharmaceutical agents for the treatment of parkisnon's disease, ADHD and microadenomas.
Baumeister et al. Historical development of the dopamine hypothesis of schizophrenia
Baumann et al. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications
CA2354237C (en) A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (adhd)
JP2954029B2 (ja) 神経活性物質の薬理学的スクリーニング法
US5744476A (en) Dopamine D1 agonists for the treatment of dementia
CN101400348A (zh) 用于提高记忆功能的四氢异喹啉衍生物
Ozaki et al. Monoamine oxidase inhibitors and procedures for their evaluation in vivo and in vitro
US20050054652A1 (en) Methods of treating metabolic syndrome using dopamine receptor agonists
WO2004010946A2 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
WO2002058687A2 (en) Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics
Baumeister et al. The serotonin hypothesis of schizophrenia: a historical case study on the heuristic value of theory in clinical neuroscience
US20040220190A1 (en) Methods of treating metabolic syndrome using dopamine receptor agonists
EP2213290A1 (en) Agent for improving motor complications or psychiatric symptoms in parkinson's disease
JP2007524620A (ja) 二重機能性化合物及びその使用
Charlton et al. Vasoconstrictor and norepinephrine potentiating action of 5-hydroxykynuramine in the isolated perfused rat kidney: involvement of serotonin receptors and alpha 1-adrenoceptors
MXPA01002946A (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
RU2508106C2 (ru) Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
RU2508096C2 (ru) Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
MXPA01007762A (en) A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (adhd) comprising a nicotine receptor partial agonist and anti-adhd agent
RU2494738C2 (ru) Применение ингибиторов пкс при трансплантации
Sušić et al. Hemodynamic effects of two ergot derivatives in the conscious spontaneously hypertensive rat
Sherry et al. 4‐fluorotranylcypromine, a novel monoamine oxidase inhibitor: Neurochemical effects in rat brain after short‐and long‐term administration
Verstraete Drugs acting on the peripheral circulation
CN1295475A (zh) 改善视神经乳头循环的药物